News - At the 6th Annual National Conference to Defeat Cancer, organized by Coalition Priorité Cancer, Merck Canada reinforced the company's continued commitment to the Quebec life sciences research innovation sector by announcing a $2-million grant to the Quebec - Consortium de recherche en oncologie clinique (Q-CROC).
News - Crowdfunding campaign for a Quebec-based company developing a tritherapy that can restore 'on-demand' walking for 45 min in experimental models of complete paralysis, wich is being tested in patients.
News - Aeterna Zentaris today announced that a poster will be presented on AEZS-134, a highly potent and selective ATP competitive Erk inhibitor, during the American Association for Cancer Research (AACR) Annual Meeting, which will be held April 5-9, 2014 in San Diego, California.
News - Aeterna Zentaris today announced that its shelf registration statement on Form F-3 previously filed with the Securities and Exchange Commission has been declared effective by the SEC. Under the shelf registration statement, the Company may offer and sell from time to time, in one or more public offerings in the United States, up to $50 million of common shares in one or more "at-the-market" distribution programs, during a 36-month period. The specifics of any particular ATM share issuance program, along with the terms and the use of proceeds of any such common shares offered by the Company will be determined at the time of any such offering and will be described in detail in a prospectus supplement or supplements filed with the SEC at the time of any such offerings.
News - A team of researchers from Université Laval and CHU de Québec identified unusually high levels of a certain protein in the brains of people suffering from essential tremor (ET), a movement disorder that affects 4% of the adult population. The discovery, the details of which were published in the most recent edition of the journal Movement Disorders, could lead to an effective treatment for this neurological condition, which is 10 times more prevalent than Parkinson’s disease.
News - Nordic Life Science Pipeline is proud to announce the appointment of Mrs France Tardif as the new Chief Financial Officer of the company as well as of Dr. Kevin O’Connor, our new acting Chief Medical Officer.
News - The Quebec – Clinical Research Organization in Cancer (Q-CROC) was awarded a $9.2 million investment from the Quebec government over four years as part of the Fonds de partenariat pour un Québec innovant et en santé (FPQIS). This public-private partnership was formally announced on February 14th, 2014 by Mr. Nicolas Marceau, the Quebec Minister of Finance and Economy. Private partners from the pharmaceutical industry and SMEs are providing matching funds, for a total investment of $18.4 million.
News - The Honourable Greg Rickford, Minister of State (Science and Technology), was in Québec City today to celebrate the new Business-Led Network of Centres of Excellence in Precision Therapeutics (PreThera Research). As a result of the 2014 Business-Led Networks of Centres of Excellence (BL-NCE) competition, PreThera Research was awarded $15 million. This support will enable the Network's researchers to apply their knowledge of biomarkers
News - Aeterna Zentaris announces that presentations on two of its oncology compounds, zoptarelin doxorubicin (AEZS-108) and disorazol Z, will be made during the 11th International Symposium on GnRH, in Salzburg, Austria, February 9 -11, 2014.
News - Atrium Innovations announces that the Superior Court of Québec issued a final order approving the previously announced plan of arrangement providing for the acquisition of all of the outstanding common shares of Atrium for cash consideration of $24.00 per common share by corporations backed by the Permira funds and the acquisition by the Corporation of all of its outstanding convertible debentures.